Edesa Biotech (EDSA) Share-based Compensation (2013 - 2026)
Edesa Biotech (EDSA) posted Share-based Compensation of $399862.0 for Q4 2025, up 6.69% sequentially from $374783.0 in Q3 2025, and up 392.54% YoY from $81183.0 in Q4 2024.
Edesa Biotech (EDSA) Share-based Compensation (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Share-based Compensation for 13 years, with the latest figure at $399862.0 in Q4 2025.
- Quarterly Share-based Compensation rose 392.54% year-over-year to $399862.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 176.99% YoY) and the FY2025 annual result came in at $700000.0, up 40.0% from the prior year.
- Share-based Compensation improved to $399862.0 in Q4 2025 per EDSA's latest filing, from $374783.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.7 million in Q2 2021 and troughed at $81183.0 in Q4 2024.
- A 5-year average of $462561.6 and a median of $354229.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation surged 23892.99% in 2021, then tumbled 82.31% in 2023.
- Over 5 years, Share-based Compensation stood at $609278.0 in 2021, then sank by 45.23% to $333675.0 in 2022, then sank by 44.75% to $184357.0 in 2023, then slumped by 55.96% to $81183.0 in 2024, then jumped by 392.54% to $399862.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $399862.0, $374783.0, and $200000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Jun 30, 2026 | 500,000.00 |
| Dec 31, 2025 | 399,862.00 |
| Dec 31, 2025 | 399,862.00 |
| Sep 30, 2025 | 374,783.00 |
| Sep 30, 2025 | 374,783.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 81,183.00 |
| Dec 31, 2024 | 81,183.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 184,357.00 |
| Dec 31, 2023 | 184,357.00 |